Llwytho...
Clinical trials of CAR-T cells in China
Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application....
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Hematol Oncol |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5651613/ https://ncbi.nlm.nih.gov/pubmed/29058636 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0535-7 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|